Selank Without Prescription: On No List, One 10 mg Vial

Almost every page that describes Selank's US status says it is "FDA category 2" or "banned from compounding". Both are wrong, and the correct version is easy to check.

FDA's compounding safety risks page carries two tables, and Selank is not in the first one. That first table is category 2, the substances that raise significant safety concerns, and under the 503A interim policies it currently names six: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10, and quinacrine hydrochloride for intrauterine administration.

The second table is headed "bulk drug substances nominated but withdrawn", described on the page as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators". Selank acetate (TP-7) appears there, alongside BPC-157, MOTS-c, Semax, epitalon, TB-500 and several others. So the accurate sentence is: Selank was nominated, was placed in category 2, and the nomination was withdrawn, which leaves it on no current category list at all.

The distinction matters practically rather than pedantically. A category 2 listing is an active determination that a substance raises significant safety concerns. A withdrawn nomination is the absence of a determination, because the nominator stopped asking. Neither is permission, and neither is approval. What both mean is that no compounder has a lawful route to it, which is the part almost every page gets right by accident while getting the reason wrong.

Section 503A of the Federal Food, Drug, and Cosmetic Act sets the conditions under which a pharmacy may compound from a bulk drug substance. In outline, the substance must be the subject of an applicable USP or NF monograph, or be a component of an FDA approved drug, or appear on the list of bulk drug substances FDA has developed for this purpose.

Selank satisfies none of the three. There is no USP or NF monograph for it. It is not a component of any approved drug, because no approved drug contains it. And it is not on the bulks list, as the May 2026 category lists confirm by omission. A withdrawn nomination is not a fourth route, and there is no provisional status that lets a pharmacy proceed while a nomination is pending, because there is no longer a pending nomination.

So the sequence that ends in a filled prescription has no first step. A physician can write anything on a pad, but a pharmacy that compounds Selank is compounding from a substance that does not meet the statutory conditions, and that is why the channel does not exist in practice rather than merely being inconvenient.

This is exactly the position occupied by the other research vials this site prices, all of which appear on the same withdrawn list with near identical language attached. Our BPC-157 regulatory page and MOTS-c regulatory page work through the same statute for those compounds. The instructive contrast is NAD+, which sits in category 1, under evaluation, where FDA has said it does not intend to take action against compounders who meet the conditions in its guidance. That is a genuinely different status, and it is why NAD+ has a clinic channel and Selank does not.

The withdrawn list does not merely record the withdrawal. It records the safety risks FDA identified while the nomination was live, and for this compound the language is specific enough to act on. Quoted in full, once:

"Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans."

Read that as three separate statements. First, the risk is immunogenicity, the possibility that a preparation provokes an immune response. Second, the identified causes are aggregation and peptide-related impurities, both of which are physical properties of a batch and both of which are measurable. Third, FDA is describing an information gap rather than an adverse finding: it lacks information, which is not the same as having found harm.

The middle statement is the useful one, because it converts a regulatory sentence into a purchase criterion. If aggregation and peptide-related impurities are the concern, then purity by HPLC, identity by mass spectrometry, and for anything injected a bacterial endotoxins result, are the tests that speak to it. A vendor either publishes them for your lot or does not.

Note also the phrase "for certain routes of administration". The risk FDA describes is route dependent, so the testing that answers it depends on what a preparation is for. That is the honest reason a certificate covering purity and identity is a reasonable document for a laboratory reagent and an incomplete one for anything else.

A dispensed medicine arrives divided, labelled with a strength, and checked by a pharmacist. A research vial arrives as none of those things, and the arithmetic that a prescription would have done for you falls to you.

The vial holds a labelled 10 mg of lyophilised powder and no solvent. It has no concentration until you give it one, and the volume you choose sets both the mg/mL and the smallest quantity a barrel can resolve.

At 2 mL the numbers are as clean as this vial gets: one unit on a U-100 barrel is 0.01 mL, which at 5 mg/mL is 50 mcg, so 10 units draws 500 mcg. Our Selank reference page works the same vial at 3 mL instead, which is 3.33 mg/mL, so treat the concentration on that page as its own figure. Reading a barrel accurately at these volumes is its own skill, covered in our syringe measurement guide.

These are laboratory handling conversions for research material. They are not dosing guidance, they are not a protocol, and nothing on this page tells anyone what to do with a vial.

Without a prescription there is no dispensing check, so the certificate is the entire quality record. Here is what the published one for this listing actually contains.

MZ Biolabs of Tucson, Arizona analysed lot 29-01260229 on 7 February 2026 and reported purity of 99.32% by HPLC-UV, with two peaks detected and the impurity peak at 6.36 minutes carrying 0.68 percent of the area. Identity was confirmed by mass spectrometry: expected monoisotopic mass 751.43 Da against a measured 751.47 Da, a gap of about 53 parts per million. Quantification by HPLC-UV returned a measured quantity of 12.29 mg per vial against a 10 mg label.

That last figure is worth more than it first appears. It means the labelled milligram is a floor rather than a ceiling on that lot, and it means the per milligram price on that lot was $1.93 rather than $2.38. It is a lot specific measurement and not a promise, and the next fill is its own number. The full working, including what a 22.9 percent overfill does to a concentration you calculated from the label, is on our Selank price breakdown.

What that certificate does not contain is the part that matters most for the concern FDA named. There is no bacterial endotoxins test and no sterility screen anywhere in it. A second certificate for the same listing does carry both: Kovera Labs certified lot 29-05260628 on 2 June 2026 at 99.371% purity and 11.86 mg net content, with an endotoxin result below 0.20 EU/mL against a 0.5 EU/mL limit by kinetic chromogenic LAL to USP Chapter 85, a rapid sterility screen returning no growth, and heavy metals under limit. That document also states plainly that its sterility method is a preliminary screen and that full compendial testing may be required for regulatory purposes.

Two certificates, one listing, different scope, which is the practical meaning of buying without a prescription. Nobody is withholding anything: both are published and the difference between them is visible in a minute. What no prescription removes is the person whose job it would be to notice. The reader who checks which lot they were sent knows more than the reader who assumed a low price implied a low standard, or that a high one implied a high standard. Neither implication holds. Read the document that matches your vial.